Scarica l'app Stockscreener
0.5445
5.68%
-0.0328
Dopo l'orario di chiusura:
.53
-0.0145
-2.66%
Vivos Therapeutics Inc Borsa (VVOS) Ultime notizie
Vivos Therapeutics Inc. (VVOS) Q1 2026 Earnings: EPS Misses Estimates as Stock DeclinesLong-Term Guidance - The League of Women Voters of Texas
Vivos Therapeutics plans rights offering for shareholders - Investing.com
Vivos Therapeutics plans rights offering for shareholders By Investing.com - Investing.com Australia
Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering - The Manila Times
Vivos plans 9‑month tradable rights for shareholders to buy stock - Stock Titan
Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients - The Manila Times
VVOS: Capital-light, scalable sleep apnea treatment model targets rapid, profitable national expansion - TradingView
VVOS: Rapidly scaling sleep apnea treatment with high margins and unique FDA-cleared devices - TradingView
Vivos Therapeutics, Inc. to Present at The Small Cap Showcase & WTR Insights on June 9, 2026 - Quiver Quantitative
Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026 - The Manila Times
Vivos Therapeutics Announces $4.5 Million Debt-to-Equity Exchange Agreement to Support Nasdaq Listing and Strengthen Financial Position – Minichart - Minichart
Vivos Therapeutics Restructures Debt to Support Nasdaq Compliance - TipRanks
Vivos Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
[8-K] Vivos Therapeutics, Inc. Reports Material Event - Stock Titan
Vivos Therapeutics agrees to debt-to-equity exchange with lender By Investing.com - Investing.com South Africa
6/5/2026 Market UpdateWinners: NOTV, STI, BGMSLosers: BIGGQ, NUWE, CYPHS&P 500: -2.6% - Trefis
Vivos Therapeutics Shares Surge After $4.5 Million Debt Conversion Fuels Nasdaq Optimism - TechStock²
Vivos Therapeutics (VVOS) Stock: Debt Exchange Plan Fuels Investor Optimism - parameter.io
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Vivos Therapeutics agrees to debt-to-equity exchange with lender - Investing.com
Vivos Therapeutics Announces Debt Exchange Agreement with Streeterville Capital to Strengthen Financial Position - Quiver Quantitative
Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing - marketscreener.com
Press Release: Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million From Streeterville Capital to Support Continued Nasdaq Listing - Moomoo
Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel® Precision Radionuclide Therapy™ - Yahoo Finance
CrowdStrike To Surge Nearly 25%? Here Are 10 Notable Analyst Calls From Thursday - Benzinga
Vivos Therapeutics (VVOS) Gains 4.5% as Stock Tests Key Resistance at $0.73Growth Stock Picks - The Legal Advocate
VVOS Should I Buy - Intellectia AI
Vivos Therapeutics Inc (VVOS) Q1 2026 Earnings Call Highlights: Revenue Surges Amid Strategic Shifts By GuruFocus - Investing.com Canada
VVOS - Finviz
Vivos Therapeutics Balances Rapid Growth With Cash Strain - The Globe and Mail
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q1 2026 Earnings Call Transcript - Insider Monkey
Vivos Therapeutics Earnings Call: Growth Meets Cash Strain - The Globe and Mail
Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update - The Manila Times
Vivos Therapeutics, Inc. 1Q 2026: Revenue $5.14M, EPS $(0.52) — 10-Q Summary - TradingView
Vivos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Vivos Therapeutics (NASDAQ: VVOS) Q1 2026 loss and going concern risk - Stock Titan
Vivos Therapeutics reports 70% revenue increase in Q1 2026 - Investing.com
Vivos Therapeutics reports 70% revenue increase in Q1 2026 By Investing.com - Investing.com Australia
BRIEF-Vivos Therapeutics Q1 Net Income USD -7.751 Million - TradingView
Press Release: Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update - Moomoo
Vivos Therapeutics Delays Quarterly Filing - TipRanks
Vivos Therapeutics (VVOS) delays Q1 10-Q; preliminary revenue up ~70% - Stock Titan
Armistice Capital (NASDAQ: VVOS) reports 8.27% holding in Vivos Therapeutics - Stock Titan
Vivos Therapeutics | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB - Moomoo
TradingKey - TradingKey
VVOS Stock Chart | VIVOS THERAPEUTICS INC (NASDAQ:VVOS) - ChartMill
[EFFECT] Vivos Therapeutics, Inc. SEC Filing - Stock Titan
Vivos targets cash flow positive operations by end of 2026 as it scales SO teams with $500,000+ monthly collections potential - MSN
Vivos Therapeutics Faces Nasdaq Listing Compliance Challenges - TipRanks
3.96M warrant shares registered by Vivos (VVOS) for resale; $2.09 strike - Stock Titan
VVOS Forecast, Price Target & Analyst Ratings | VIVOS THERAPEUTICS INC (NASDAQ:VVOS) - ChartMill
Vivos Therapeutics (VVOS) price target decreased by 51.67% to 2.47 - MSN
Broadcom, Vivos Therapeutics and 3 stocks to watch heading into Monday - MSN
Vivos Therapeutics (NASDAQ: VVOS) registers 3.96M warrant-linked shares for resale - Stock Titan
1.21%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):